Zevra Therapeutics, Inc. Common Stock (ZVRA) is a publicly traded Healthcare sector company. As of May 21, 2026, ZVRA trades at $10.18 with a market cap of $616.57M and a P/E ratio of 7.30. ZVRA moved +0.20% today. Year to date, ZVRA is +22.78%; over the trailing twelve months it is +18.93%. Its 52-week range spans $6.19 to $13.16. Analyst consensus is strong buy with an average price target of $24.00. Rallies surfaces ZVRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes ZVRA SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $10.18 |
| Market Cap | $616.57M |
| P/E Ratio | 7.30 |
| EPS | $1.40 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.16 |
| 52-Week Low | $6.19 |
| Volume | 40 |
| Avg Volume | 0 |
| Revenue (TTM) | $106.47M |
| Net Income | $83.23M |
| Gross Margin | 0.00% |
7 analysts cover ZVRA: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $24.00.